Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Coffin (1995)
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapyScience, 267
A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, Paaline Schipper, H. Mo, M. Markowitz, T. Chernyavskiy, Ping Niu, N. Lyons, A. Hsu, G. Granneman, D. Ho, C. Boucher, J. Leonard, D. Norbeck, D. Kempf (1996)
Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 2
Condra (1995)
Evidence for the existence of long-lived genetic reservoirs of HIV-1 in infected patientsJ Acq Immun Def Synd Hum Retrovirol, 10
Boucher Boucher (1996)
Rational approaches to resistance — using saquinavirAIDS, 10
H. Jacobsen, M. Haenggi, M. Ott, I. Duncan, M. Andreoni, S. Vella, J. Mous (1996)
Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.Antiviral research, 29 1
A. Patick, H. Mo, M. Markowitz, K. Appelt, Bo-Wen Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, S. Webber (1996)
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus proteaseAntimicrobial Agents and Chemotherapy, 40
J. Condra, W. Schleif, O. Blahy, L. Gabryelski, D. Graham, J. Quintero, A. Rhodes, H. Robbins, E. Roth, M. Shivaprakash, Donna Titus, Tao Yang, Hedy Tepplert, K. Squires, P. Deutsch, E. Emini (1995)
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 374
M. Kozal, Nila Shah, Naiping Shen, R. Yang, R. Fucini, T. Merigan, D. Richman, Don Morris, E. Hubbell, M. Chee, T. Gingeras (1996)
Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arraysNature Medicine, 2
Patick (1996)
Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavirAntivir Ther, 1
J. Partaledis, K. Yamaguchi, M. Tisdale, E. Blair, Cristina Falcione, B. Maschera, Richard Myers, S. Pazhanisamy, O. Futer, Aine Cullinan, C. Stuver, R. Byrn, D. Livingston (1995)
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl proteaseJournal of Virology, 69
H. Schock, V. Garsky, L. Kuo (1996)
Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical TrialsThe Journal of Biological Chemistry, 271
Smith (1996)
Selection for high-level resistance to HIV-1 protease inhibitors used in pairsAntivir Ther, 1
J. Vacca, J. Condra (1997)
Clinically effective HIV-1 protease inhibitorsDrug Discovery Today, 2
J. Condra, D. Holder, W. Schleif, O. Blahy, R. Danovich, L. Gabryelski, D. Graham, Donna Laird, J. Quintero, A. Rhodes, H. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. Chodakewitz, P. Deutsch, R. Leavitt, F. Massari, J. Mellors, K. Squires, R. Steigbigel, H. Teppler, E. Emini (1996)
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorJournal of Virology, 70
M. Tisdale, R. Myers, B. Maschera, N. Parry, N. Oliver, E. Blair (1995)
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitorsAntimicrobial Agents and Chemotherapy, 39
J. Schmit, L. Ruiz, B. Clotet, A. Raventós, J. Tor, J. Leonard, J. Desmyter, E. Clercq, A. Vandamme (1996)
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)AIDS, 10
Condra (1997)
Preventing HIV-1 drug resistanceScience & Medicine, 4
Summary. Resistance to the HIV‐1 protease inhibitor indinavir involves the accumulation of multiple amino acid substitutions in the viral protease. A minimum of 11 amino acid positions have been identified as potential contributors to phenotypic resistance. Three or more amino acid substitutions in the protease are required before resistance becomes measurable (≥four‐fold). Further losses in susceptibility follow the stepwise accumulation of additional amino acid substitutions, indicating that antiviral activity (selective pressure) is maintained despite the appearance of multiple amino acid substitutions in the viral protease. Importantly, the sequential nature of these changes indicates that the effects of these substitutions are additive, and that the evolution of resistance is driven by viral replication. This result has significant implications for therapy. It predicts that viral variants resistant to indinavir are unlikely to pre‐exist in protease inhibitor‐naive patients, and further, that high‐level resistance can only develop if the virus is allowed to replicate in the presence of the drug. The use of indinavir in combination with other antiretroviral agents has been demonstrated to dramatically reduce the incidence of resistance mutations, suggesting that with maximal suppression of viral replication, long‐term control of HIV‐1 infection may be achievable. Thus, the goal of therapy must be to never to allow the virus to replicate. This can be best accomplished by initiating therapy with a maximally suppressive regimen, to reduce viral replication as much as possible, and by imposing a high genetic barrier to resistance. Previous use of other protease inhibitors or inadequate adherence to therapy may compromise the long‐term benefit of indinavir by allowing the virus to gain a foothold through the development of resistance. An understanding of these issues will be critical in realizing the full potential of this potent new drug for the control of HIV‐1 infection.
Haemophilia – Wiley
Published: Jul 1, 1998
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.